Express News | Ventyx Biosciences Inc: Expect to Report Topline Results From This Trial in 2025.
Express News | Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of Vtx3232 in Patients With Early Parkinson’s Disease
Express News | Ventyx Biosciences: Roy Gonzales Assumed Roles of Interim Principal Financial Officer and Interim Principal Accounting Officer
Express News | Ventyx Biosciences Announces Departure of Chief Financial Officer
Press Release: Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Wells Fargo Maintains Overweight on Ventyx Biosciences, Lowers Price Target to $11
Ventyx Biosciences Is Maintained at Buy by Canaccord Genuity
Express News | Ventyx Biosciences Inc : Canaccord Genuity Cuts Target Price to $14 From $15
Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer
Ventyx Biosciences: A Buy Rating Backed by Promising Clinical Trials and Strong Financials
Ventyx Biosciences: A Cautious Hold Amid Intensifying Competition in Obesity Treatment Market
Ventyx Biosciences GAAP EPS of -$0.45
Ventyx Biosciences Q2 EPS $(0.45) Beats $(0.57) Estimate
Express News | Ventyx Biosciences Inc Q3 Shr View $-0.57 -- LSEG IBES Data
Express News | Ventyx Biosciences Qtrly Shr Loss $0.45
Express News | Ventyx Biosciences : Cash, Cash Equivalents and Marketable Securities as of June 30, Expected to Fund Planned Operations Into at Least 2H of 2026
Ventyx Biosciences | 10-Q: Q2 2024 Earnings Report
Earnings Flash (VTYX) VENTYX BIOSCIENCES Posts Q2 Loss $-0.45
Express News | Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress